Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medinotec (MDNC) Research & Development (2022 - 2025)

Medinotec filings provide 4 years of Research & Development readings, the most recent being $8326.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 87.98% to $8326.0 in Q4 2025 year-over-year; TTM through Nov 2025 was -$151728.0, a 993.36% decrease, with the full-year FY2025 number at -$91133.0, down 307.74% from a year prior.
  • Research & Development hit $8326.0 in Q4 2025 for Medinotec, down from $66235.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $69270.0 in Q4 2024 to a low of -$177275.0 in Q1 2025.
  • Median Research & Development over the past 4 years was $2310.0 (2023), compared with a mean of -$13789.8.
  • Biggest five-year swings in Research & Development: tumbled 562.29% in 2024 and later surged 3400.79% in 2025.
  • Medinotec's Research & Development stood at $6405.0 in 2022, then plummeted by 57.41% to $2728.0 in 2023, then soared by 2439.22% to $69270.0 in 2024, then plummeted by 87.98% to $8326.0 in 2025.
  • The last three reported values for Research & Development were $8326.0 (Q4 2025), $66235.0 (Q3 2025), and -$49014.0 (Q2 2025) per Business Quant data.